INGESTEM gather five research INSERM Units and platforms:


An infrastructure of excellence:

  • Pioneering centers in the derivation of the first human embryonic stem (ES) cells in France, with the authorization of the Agence de la Biomedicine, since 2005.
  • Leaders in the field of induced pluripotent stem cells (iPS) cell reprogramming, since 2007.
  • Complementary expertise including cell engineering, genome editing, transgenesis, large-scale and automated cell factory and molecular high-throughput screening for preclinical, clinical and industrial applications.